Cue Biopharma, Inc. (CUE)

CUE Biopharma is a clinical-stage biopharmaceutical company developing precision immuno-engineered therapies for allergic and autoimmune diseases. The company's lead programs include CUE-221, an anti-IgE therapy in Phase 2 for allergic diseases, and CUE-401, a bifunctional IL-2 and TGF-β candidate in Phase 1 development designed to restore immune tolerance.